{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:43:11Z","timestamp":1780098191428,"version":"3.54.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017088","name":"Translational Breast Cancer Research Consortium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017088","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013566","name":"Terri Brodeur Breast Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009634","name":"Susan G. Komen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clbc.2024.12.018","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T12:01:43Z","timestamp":1735646503000},"page":"e419-e430.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134\/TBCRC 012\/ABCDE Clinical Trials"],"prefix":"10.1016","volume":"25","author":[{"given":"Dario","family":"Trapani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine E.","family":"Reeder-Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Traina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Falkson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ligibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Come","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju","family":"Nohria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Ryabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabihah","family":"Tayob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara M","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica L.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2024.12.018_bib0001","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0002","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0003","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2024.12.018_bib0004","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0006","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0007","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and Bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0008","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.6004\/jnccn.2011.0112","article-title":"Avastin for breast cancer, 2005-2011: requiescat in pacem?","volume":"9","author":"Burstein","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2024.12.018_bib0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrclinonc.2015.131","article-title":"Clinical overview of metronomic chemotherapy in breast cancer","volume":"12","author":"Munzone","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0011","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2407-6-225","article-title":"Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer","volume":"6","author":"Orlando","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clbc.2024.12.018_bib0013","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/01.cad.0000224454.46824.fc","article-title":"Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer","volume":"17","author":"Orlando","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clbc.2024.12.018_bib0014","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.2009.24.0143","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2011.06.040","article-title":"Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer","volume":"48","author":"Fedele","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2024.12.018_bib0016","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-014-2492-y","article-title":"A phase II study of metronomic paclitaxel\/cyclophosphamide\/capecitabine followed by 5-fluorouracil\/epirubicin\/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing\/HER2-negative primary breast cancer","volume":"74","author":"Masuda","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0017","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2005.04.5773","article-title":"Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients","volume":"24","author":"Bottini","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0018","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1200\/JCO.2020.38.15_suppl.507","article-title":"Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001)","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0019","first-page":"284","article-title":"Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study","volume":"3","author":"Nasr","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/jco.2007.25.18_suppl.561","article-title":"A pilot study of adjuvant bevacizumab after neoadjuvant chemotherapy for high-risk breast cancer","volume":"25","author":"Mayer","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0021","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/jco.2008.26.15_suppl.519","article-title":"A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer","volume":"26","author":"Mayer","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0022","doi-asserted-by":"crossref","first-page":"TPS103","DOI":"10.1200\/jco.2010.28.15_suppl.tps103","article-title":"TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer","volume":"28","author":"Mayer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0023","doi-asserted-by":"crossref","first-page":"OT3-02-04","DOI":"10.1158\/0008-5472.SABCS11-OT3-02-04","article-title":"OT3-02-04: TBCRC 012: ABCDE, a phase II randomized study of adjuvant Bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer","volume":"71","author":"Mayer","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.12.018_bib0024","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1538-7445.AM2019-193","article-title":"Antiangiogenic effect of conditioned media derived from triple negative breast cancer cells in brain microvascular endothelial cells in vitro [abstract]","volume":"79","author":"Ayoub","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.12.018_bib0026","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1634\/theoncologist.2009-0155","article-title":"Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials","volume":"15","author":"Geiger-Gritsch","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2024.12.018_bib0027","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0028","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0029","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.clbc.2024.12.018_bib0030","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1200\/JCO.2018.79.2028","article-title":"Double-blind Phase III trial of Adjuvant chemotherapy with and without Bevacizumab in patients with lymph node\u2013Positive and high-risk lymph node\u2013Negative breast cancer (E5103)","volume":"36","author":"Miller","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0031","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.breast.2015.02.036","article-title":"Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: a randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine","volume":"24","author":"Curigliano","year":"2015","journal-title":"Breast"},{"key":"10.1016\/j.clbc.2024.12.018_bib0032","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102326","article-title":"Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: an individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature","volume":"103","author":"Lombardi","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clbc.2024.12.018_bib0034","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.2015.65.6595","article-title":"Low-dose oral cyclophosphamide and methotrexate maintenance for hormone receptor-negative early breast cancer: international Breast Cancer Study Group trial 22-00","volume":"34","author":"Colleoni","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0035","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"Wang","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clbc.2024.12.018_bib0036","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/CCO.0000000000000893","article-title":"Postneoadjuvant treatment for triple-negative breast cancer","volume":"34","author":"Trapani","year":"2022","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0037","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1200\/JCO.21.00976","article-title":"Randomized phase III postoperative trial of platinum-based chemotherapy versus Capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0038","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1200\/JCO.21.01657","article-title":"BRE12-158: a postneoadjuvant, randomized phase II trial of personalized therapy versus treatment of physician's choice for patients with residual triple-negative breast cancer","volume":"40","author":"Schneider","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0039","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0040","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with Pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0041","doi-asserted-by":"crossref","first-page":"LBA500","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA500","article-title":"A-BRAVE trial: a phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy","volume":"42","author":"Conte","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0042","doi-asserted-by":"crossref","first-page":"GS01","DOI":"10.1158\/1538-7445.SABCS23-GS01-03","article-title":"Abstract GS01-03: adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA\/IMpassion030 phase 3 trial","volume":"84","author":"Ignatiadis","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.12.018_bib0043","doi-asserted-by":"crossref","first-page":"113952","DOI":"10.1016\/j.ejca.2024.113952","article-title":"Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA\/IMpassion030 phase 3 trial","volume":"200","author":"McArthur","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2024.12.018_bib0044","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0045","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in <em>BRCA1\/2<\/em>and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0046","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0047","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0048","doi-asserted-by":"crossref","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0049","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jamaoncol.2019.1838","article-title":"Assessment of molecular relapse detection in early-stage breast cancer","volume":"5","author":"Garcia-Murillas","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0050","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1158\/1078-0432.CCR-19-3005","article-title":"Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer","volume":"26","author":"Parsons","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2024.12.018_bib0051","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0052","doi-asserted-by":"crossref","first-page":"GS3","DOI":"10.1158\/1538-7445.SABCS21-GS3-06","article-title":"Abstract GS3-06: Primary results of the cTRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer","volume":"82","author":"Turner","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.12.018_bib0053","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-23-0757","article-title":"Molecular residual disease in breast cancer: detection and therapeutic interception","volume":"29","author":"Medford","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2024.12.018_bib0054","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMp1900079","article-title":"Residual disease after neoadjuvant therapy - developing drugs for high-risk early breast cancer","volume":"380","author":"Prowell","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.12.018_bib0055","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1200\/JCO.2018.79.2028","article-title":"Double-blind Phase III trial of Adjuvant chemotherapy with and without Bevacizumab in patients with lymph node\u2013Positive and high-risk lymph node\u2013Negative breast cancer (E5103)","volume":"36","author":"Miller","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0056","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/annonc\/mdw665","article-title":"Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer","volume":"28","author":"Bell","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0057","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1158\/0008-5472.SABCS13-S1-03","article-title":"Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab \u00b1 bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer [abstract]","volume":"73","author":"Slamon","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.12.018_bib0058","doi-asserted-by":"crossref","first-page":"TPS602","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS602","article-title":"Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA","volume":"39","author":"Marm\u00e9","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0059","doi-asserted-by":"crossref","first-page":"TPS619","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS619","volume":"41","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0060","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clbc.2024.12.018_bib0061","doi-asserted-by":"crossref","first-page":"OT1-02-04","DOI":"10.1158\/1538-7445.SABCS17-OT1-02-04","volume":"78","author":"Pusztai","year":"2018","journal-title":"Cancer Res"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:56:13Z","timestamp":1762548973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924003719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1526820924003719"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.018","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134\/TBCRC 012\/ABCDE Clinical Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}